AREDS 2 is a nationwide study to determine whether high dose carotenoids (lutein and zeaxanthin) and omega-3 fatty acids (DHA and EPA) can slow vision loss in people at moderate to high risk for the progression of AMD. The study began in the fall of 2006, and is expected to be completed in 2013.
The 3 interventions arms for the carotenoids and omega-3s are: 1) 10 mg of lutein and 2 mg of zeaxanthin plus placebo; 2) 350 mg of DHA and 650 mg of EPA plus placebo; and 3) a combination of the DHA/EPA and lutein/ zeazanthin. In addition, all participants are offered the original AREDS formula (now considered standard of care) or 3 variations of this formula: (1) no beta-carotene; (2) lower amounts of zinc; and (3) no beta-carotene and lower zinc.
At the Association for Research in Vision and Ophthalmology's meeting in May, researchers presented the baseline demographic and dietary characteristics of AREDS 2 participants, and their associations with AMD (1). They report that people consuming the most DHA or EPA had the lowest rating of AMD severity.
Study Design
Baseline fundus photographs were centrally graded with a standardized protocol using drusen size and pigment characteristics to assign the AREDS
5 level simple scale score of severity. Participants completed a dietary assessment at baseline, and nutrient density values were classified into quintiles. Data were adjusted for age, gender and
Results
Demographic characteristics are shown in Table 1. Dietary DHA and EPA were inversely related to AMD severity score in energy-adjusted comparisons of highest versus lowest quintile intake (p<0.05 for both nutrients, see Table 2). Trend tests on quintile median nutrient values yielded a p-value of <0.01 for both EPA and DHA. The association of lutein and zeaxanthin intake with severity score was in the direction of benefit, but did not achieve statistical significance.
Comments
At baseline, AREDS 2 participants had good visual function in their study eye(s). The majority had large drusen and/or pigmentary changes in the retinal pigment epithelium, risk factors for progression to advanced AMD. The authors conclude that those with the highest intake of DHA or EPA were significantly less likely than their peers to have higher AMD severity scores.
References
Chang JR, et al. Demographic and dietary characteristics of the Age-Related Eye Disease Study 2 (AREDS2) participants and their associations with age-related macular degeneration (AMD). ARVO May 2-6, 2010, Ft. Lauderdale, FL, e-Abs 97.
Growing evidence suggests lutein and zeaxanthin play an important role in protection against AMD by filtering out blue light or quenching free radicals. While much remains to be learned, researchers from Waterford Institute and Regional Hospital in Ireland and the University of Utah’s Moran Eye Center have reviewed mechanisms involved in absorption and transport of these carotenoids, their uptake by the retina and how they are stabilized (1). Below are highlights of these findings, along with editorial comment on implications for diet, lifestyle and supplement use.
Absorption of Lutein and Zeaxanthin
Dietary fat is important for the absorption of xanthophyll carotenoids like lutein and zeaxanthin. Fat stimulates bile flow from the gall bladder to emulsify fat-soluble vitamins into lipid micelles – microscopic fat droplets – so they can be absorbed in the small intestine. Inadequate fat intake can result in reduced absorption of carotenoids, even if the diet is carotenoid-rich. Experimental data suggest absorption of lutein is mediated by a non-specific transporter protein (this protein, scavenger receptor class B type I, appears to play a primary role in intestinal absorption, but other proteins or passive diffusion may also be involved). Of note, some competition for absorption is seen when similarly structured carotenoids like beta-carotene and lutein are consumed together.
Comments: Though different carotenoids compete for absorption, some evidence suggests that balanced amounts of various carotenoids consumed together over time don’t interfere with each other in terms of bioavailability (2). Importantly, doses of lutein (10 mg) and zeaxanthin (2 mg) now being used in the AREDS 2 trial, did not reduce serum levels of other important carotenoids in a dosing study (3).
Transport of Lutein and Zeaxanthin
Dietary lutein and zeaxanthin are delivered to the retina via plasma lipoproteins, chiefly LDL and HDL cholesterol. While LDL is the primary carrier for most carotenoids, LDL and HDL carry about equal amounts of lutein and zeaxanthin. Several studies suggest relatively low HDL levels could hinder transport and capture of these carotenoids. Lower HDL levels have been found in overweight and obese individuals, for example, and higher body fat percentage is linked to risk of AMD progression as well as to lower macular pigment density. Lipoproteins also include protein components known as apolipoproteins. Researchers are investigating whether a person’s apolipoprotein profile might influence transport and delivery of these carotenoids to the retina. Of many apolipoproteins types, ApoE has the strongest link with AMD.
Comments: Lower levels of HDL have been found in overweight individuals, consistent with the possibility that a relative lack of HDL may impair transport and/or retinal capture of the carotenoids. Obesity has been identified as a risk factor for AMD. Take home message? Aerobic exercise, which aids weight loss and increases HDL, may prove useful in lowering AMD risk.
Retinal Uptake of the Xanthophyll Carotenoids
The mechanisms governing retinal capture and accumulation of lutein and zeaxanthin to the exclusion of other carotenoids are still poorly understood. However, retinal capture of xanthophyll carotenoids is performed by xanthophyll-binding proteins (XBP). XBPs may also be involved in: a) stabilizing xanthophylls in cell membranes, the cytosol or the cytoskeleton, b) mediating inter-conversion of lutein, zeaxanthin and various metabolites within the retina, and c) facilitating antioxidant activity of macular carotenoids. Importantly, it has been found that XBPs can become saturated, with implications for xanthophyll carotenoid supplementation.
Comments: Macular pigment density often increases dramatically in the first 4 weeks of supplementation, and then levels off. In a number of studies testing 10-12 mg of lutein, macular pigment density reached a plateau after the first month. This may be due to saturation of binding proteins, and suggests higher doses may not further enhance macular pigment over time.
References
Loane E, et al. Transport and retinal capture of lutein and zeaxanthin with reference to age-related macular Degeneration. Surv Ophthalmol 53:68-81, 2008.
Tyssandier V, et al. Vegetable-borne lutein, lycopene, and beta-carotene compete for incorporation into chylomicrons, with no adverse effect on the medium-term (3-wk) plasma status of carotenoids in humans. Am J Clin Nutr 75:526–34 2002.
Rosenthal JM, et al. Dose-ranging study of lutein supplementation in persons aged 60 years or older.Invest Ophthalmol Vis Sci 47:5227–233, 2006.
Age-related macular degeneration (AMD) is a major cause of irreversible vision loss among people of Western European ancestry. It’s estimated that 3.35 million Europeans and 1.75 million Americans are living with sight-threatening AMD. Over the next 20 years these numbers are expected to increase by 50% if preventive interventions aren’t identified. Finding low cost ways to prevent progression to advanced AMD is particularly important since treatments for wet AMD are limited in scope, invasive, costly and may result in complications as severe as end-stage disease.
National Eye Institute researchers have examined whether omega-3 intake is associated with a reduced likelihood of developing central geographic atrophy and neovascular AMD in a cohort within AREDS – a multicenter clinical trial, which ran from 1992 to 2005. The investigators report that participants with the highest omega-3 intake were 30% less likely than their peers to develop dry or wet AMD.
Study Design
The research team looked at a sub-group of 1,837 AREDS participants considered to be at moderate-to-high risk of advanced AMD. Baseline data of omega-3 intake was obtained using a validated food-frequency questionnaire. Trained fundus graders ascertained AMD status from annual stereoscopic color photos by using standardized methods at a single reading center across a 12-year period.
Results
Nearly 20% of participants progressed to dry AMD, and about 32% progressed to wet AMD over the 12-year period. Those in the highest quintile of combined EPA and DHA intake were 30% less likely to develop dry and wet AMD than their peers in the lowest intake quintile. Median intake in the highest quintile was 11% of total calories, based on 2000 kcal daily.
Comments
“If these results are generalizable, they may guide the development of low-cost and easily implemented preventive interventions for progression to advanced AMD”, according to the researchers led by John Paul SanGiovanni. A 4000-person, 5-year randomized clinical trial designed to test the efficacy of omega-3 for this purpose is now underway (www.areds2.org). The omega-3 fatty acids may work by multiple mechanisms. For example, AMD appears to have an inflammatory etiology, and the omega-3s have the capacity to affect pathologic inflammatory processes in the retina.
Reference
SanGiovani et al. ω-3 Long-chain polyunsaturated fatty acid intake and 12-y incidence of neovascular age-related macular degeneration and central geographic atrophy: a prospective cohort study from the Age-Related Eye Disease Study. Am J Clin Nutr [Epub Oct, 2009].
It is known that omega-3
fatty acids, particularly DHA,
play an important role in the layer of nerve cells in the retina,
and studies have already reported that omega-3
may protect against the onset of AMD. A meta-analysis, for example,
reported in the June, 2008 issue of the Archives of Ophthalmology
found that a high intake of omega-3s
and fish may reduce the risk of AMD by up to 38%. The Australian
authors of this review noted that the benefits of omega-3
were most pronounced against more advanced AMD, while twice weekly
fish consumption was associated with a lower risk of both early
and late AMD (1).
In line with the epidemiologic data, are
the results of a new National Eye Institute study which found
that omega-3
fatty acids could retard the progression of lesions in a murine
mouse model of AMD (2). Even more
intriguing are the findings that mice in the high omega-3
group displayed some reversion of the lesions.
Study Design and Methods
The study evaluated the effects of a high
omega-3
diet on the retinas of Cc12 - / - / Cx3cr1- / - mice - a model
that develops AMD-like retinal lesions that include focal deep
retinal lesions, abnormal retinal pigment epithelium, photoreceptor
degeneration, and accumulation of A2E, a component of human retinal
lipofuscin (an aging pigment and likely product of lipid peroxidation).
The mice were raised on low or high omega-3
diets, and clinical endpoints were measured using fundus photography,
histopathology, transmission electron microscopy, A2E extraction
and enzyme-linked immunoabsorbant assay to evaluate serum prostaglandin
levels.
Results
Mice that were fed the high omega-3
diet showed a slower progression of lesions compared to the low
omega-3
fed mice. Some mice ingesting the high omega-3
diet exhibited regression of lesions. No retinal lesions were
noted in the normal wild mice used as controls and fed a regular
diet.
Compared to the low omega-3
group, mice consuming the omega-3
enriched diet had lower levels of inflammatory molecules such
as prostaglandin E2 and leukotriene B4, and higher levels of anti-inflammatory
mediators such as prostaglandin D2. Higher omega-3
also resulted in lower IL-6 transcript levels and concentrations
of ocular TNF-alpha, an inflammatory cytokine.
Comments
In summary, a diet enriched in EPA
and DHA
ameliorated the progression of retinal lesions in this useful
animal model of AMD. These results are supportive of the findings
from population health studies, and await further confirmation
in humans by the AREDS 2 trial in progress.
EPA
and DHA
are concentrated in the retina and retinal vascular endothelium,
and DHA
accounts for about 50% of the lipids in photoreceptor rod outer
segments. Vital retinal functions, including damage repair, depend
on the existence of adequate levels of DHA.
In the eye, the omega-3
fatty acids and their derivatives play an extensive role in many
biologic processes such as the inflammatory cascade, apoptosis
and neuroprotection. In this study, the researchers focused on
the function of the omega-3s
in inflammation, since the role of inflammation in the pathogenesis
of AMD is evident. Arachidonic acid, an omega-6 fatty acid, is
the starting material for the synthesis of pro-inflammatory mediators
such as various cytokines. When fish oil is provided, EPA
and DHA
are incorporated into cellular membranes at the expense of arachidonic
acid.
References
Chong EW, et al. Dietary omega-3 fatty acid
and fish intake in the primary prevention of age-related macular
degeneration: a systematic review and meta-analysis. Archives
of Ophthalmology 126:826-33, 2008.
Tuo J, et al. A high omega-3 fatty acid diet
reduces retinal lesions in a murine model of macular degeneration.
American Journal of Pathology 175:799-807, 2009.
Modifiable risk factors responsible for many
premature or preventable deaths fall into three main categories:
Lifestyle factors such as smoking and physical inactivity; Dietary
risk factors such as a high salt intake and a low intake of fruits
and vegetables; And "metabolic" risk factors, such as obesity
and hypertension, which shorten life expectancy by increasing
the odds of developing CVD and diabetes.
With health care costs skyrocketing, it's
important to know how many deaths are caused by each risk factor
before developing policies and programs to improve the nation's
health. Although previous studies have provided some information,
they have not used consistent and comparable methods to estimate
the number of deaths attributable to different risk factors. In
addition, previous studies have rarely considered dietary and
metabolic risk factors.
In a new study, jointly funded by the CDC
and the Association of Schools of Public Health, Harvard researchers
estimated the number of deaths due to 12 different modifiable
risk factors.
Study Methods and Findings
The researchers used a method called "comparative
risk assessment." They retrieved data on exposures to the 12 selected
risk factors from US national health surveys, and obtained information
on deaths from different diseases from the US National Health
Center for Health Statistics. They also used previously published
studies to estimate how much each risk factor increased the risk
from a disease, and applied a mathematical model to estimate the
number of deaths related to each factor.
Smoking and high blood pressure, which both
have effective interventions, are responsible for the largest
number of preventable deaths, followed by obesity, physical inactivity
and high salt intake. Notably, 84,000 deaths were attributable
to insufficient omega-3
intake, slightly higher than high trans fatty acid intake (82,000).
Though the study focused upon the most common
causes of death such as cancer, heart disease and respiratory
diseases, the findings that inadequate consumption of omega-3,
and fruits and vegetables are important risk factors may be notable
for visual health as well. EPA
and DHA
(from fish), as well as lutein
and zeaxanthin
(from produce), have been strongly linked to the risk of AMD and,
possibly, other ocular conditions. The typical intake of EPA
and DHA
for example is 100-200 mg daily, while the AREDS-2 trial is testing
1,000 mg. In addition, 10 mg of lutein
and 2 mg of zeaxanthin
are being employed in AREDS-2, while the average daily consumption
of these carotenoids is 2 mg.
Reference
Danaei G, et al. The Preventable Causes of Death
in the United States: Comparative Risk Assessment of Dietary,
Lifestyle, and Metabolic Risk Factors. PLoS Med 6(4): e1000058.
Preventing Age-Related Macular Degeneration (AMD) and delaying its progression would best preserve people's quality of life while containing health care system costs. The results from two new analyses suggest that adopting dietary habits or using supplements that slow progression from early to late stages, could ease the future burden of this disease.
Combined Dietary Factors Reduce AMD Risk
Foods provide many nutrients that may interact to modify the risk for AMD. Therefore, instead of looking at isolated nutrients, researchers from Tufts University developed a composite scoring system to examine the combined effect of dietary nutrients on AMD risk.
Study Design and Results
Data was analyzed for 4,003 Age-Related Eye Disease Study (AREDS) participants, involving 7,934 eyes. Levels of AMD-protective nutrients, including vitamins C and E, zinc, lutein, zeaxanthin, omega-3 fatty acids (DHA and EPA), as well as low-GI (Glycemic Index) foods, were assessed using participants' food intake reports. Each dietary factor was assigned a percentile score, and factor scores were added up to find each participant's compound score. Compound scores were related to participants' AMD risk, based on stereoscopic fundus photographs of the macula taken when they joined AREDS.
Participants whose diets included higher levels of these protective nutrients and of low-GI foods were at substantially lower risk for early and advanced AMD. Validation analyses showed the relationships to be robust.
Conclusion and Comments
The results suggest that the compound score summarizing the overall effect of diets rich in the AREDS trial nutrients (vitamin C, vitamin E, and zinc), the AREDS 2 trial nutrients (DHA, EPA, lutein and zeaxanthin), and low-GI foods are independently associated with lower risk for prevalent drusen and advanced AMD. Beta-carotene did not affect risk levels. The findings are in accord with earlier research linking low GI-diets with reduced risk of AMD and cataract, and further research is warranted.
New Therapies May Mitigate Rise in AMD
The Vision Health Cost-Effectiveness Study Group - encompassing investigators from the CDC, the National Center for Chronic Disease and Prevention and other institutions - report that while the prevalence of AMD will increase substantially by 2050, the use of new therapies can mitigate its effects.
Study Design and Results
The study simulated cases of early AMD, choroidal neovascularization (CNV), geographic atrophy (GA), and AMD-attributable visual impairment and blindness with five possible scenarios:
(1) No treatment;
(2) Focal laser and photodynamic therapy (PDT) for CNV;
(3) Vitamin prophylaxis at early-AMD incidence with focal laser/PDT for CNV;
(4) No vitamin prophylaxis followed by focal laser treatment for extra and juxtafoveal CNV and anti-vascular endothelial growth factor treatment;
(5) Vitamin prophylaxis at early-AMD incidence followed by CNV treatment, as in scenario (4).
Cases of early AMD nearly doubled, increasing from 9.1 million in 2010 to 17.8 million in 2050 across all scenarios. In non-vitamin-receiving scenarios, cases of CNV and GA increased from 1.7 million in 2010 to 3.8 million in 2050 (25% lower in vitamin-receiving scenarios). Cases of visual impairment and blindness increased from 620,000 in 2010 to 1.6 million in 2050 when given no treatment and were 2%, 22%, 17%, and 35% lower in scenarios 2, 3, 4, and 5, respectively (see Figure 2E).
Figure 2E Number of Americans with pre-vision-threatening age-related macular degeneration (AMD) and blindness, with 5 alternative treatment scenarios from 2010 to 2050. Scenario 1 indicates no treatment (baseline); scenario 2, focal laser or photodynamic therapy (PDT) for CNV; scenario 3, universal vitamin prophylaxis at early AMD incidence with focal laser or PDT for CNV treatment; scenario 4, no vitamin prophylaxis followed by focal laser treatment for extrafoveal and juxtafoveal CNV and anti-vascular endothelial growth factor (anti-VEGF) treatments for subfoveal CNV for 2 years followed by PDT; scenario 5, universal vitamin prophylaxis followed by focal laser and anti-VEGF treatments for subfoveal CNV for 2 years followed by PDT.
Conclusion and Comments
The authors found that use of vitamins and existing therapies could reduce AMD by as much as 35%, translating to 565,000 fewer cases of visual impairment and blindness in 2050.
A 23% reduction in cases of visual impairment and blindness could be achieved using only vitamin prophylaxis in conjunction with focal laser and PDT therapies for patients who develop CNV - which amounts to a reduction of 375,000 cases of visual impairment and blindness five decades from now.
According to the authors, additional efforts to expand the use of AREDS level dietary supplements Is a cost-effective method of delaying AMD progression and cost-effective use of health care resources. However, research indicates it is not widely used among patients with early-stage disease and the correct dosage is seldom used. For example, though 68% of patients with early AMD who visited a retinal specialty practice in Edmonton, Canada, took some form of AREDS-recommended antioxidant supplement, no patients were taking the correct dosage of all 4 recommended vitamins. Public prevention efforts should focus on expanding the use of antioxidant vitamins in people with early AMD, and ensuring that these patients use the correct dosage.
References
Chiu, C-J, et al. Dietary compound score and risk of age-related macular degeneration in the AREDS. Ophthalmology 116:939-46, 2009.
Rein DB et al. Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. Arch Ophthalmol 127:533-40, 2009.
The heart benefits of the traditional Mediterranean diet high in fish, fresh produce and red wine, have been well documented. A new study, part of the European IMMIDIET project, has shed new light on one of red wine's positive cardiovascular benefits.
The aim of the IMMIDIET project, funded by the European Union's initiative on food nutrition and health, is to examine the role of genetic and lifestyle factors in CVD prevention in Italians living at home, as wells as Italian immigrants to other countries.
High dietary and plasma concentrations of the marine fatty acids EPA and DHA are known to be protective against coronary heart disease (CHD) and sudden cardiac death. Alcohol, too, lowers the risk of ischemic stroke and CHD via a number of proposed pathways: increasing HDL, decreasing platelet aggregation and coagulation factors and exerting beneficial effects on endothelial function and inflammation.
Evidence also suggests that alcohol influences fatty acid metabolism. Low alcohol intake appears to increase long-chain fatty acid concentrations, while high alcohol decreases their concentration. Alcohol-induced increases in marine fatty acids might be a unique cardio-protective mechanism of alcohol.
In IMMIDIET, the researchers examined whether the heart benefits of alcohol extend to healthy men and women as well as male patients with cardiovascular disease as was shown in a previous study, the Lyon Diet Heart Study. They also examined whether various alcoholic beverages might affect marine lipid concentrations differently.
Study Design and Methods
In the framework of IMMIDIET, 1,604 men and women aged 26-65 years were enrolled in Italy, Belgium and England. A food frequency questionnaire was used to evaluate dietary and beverage intake. Blood samples were obtained, and plasma and red blood cell omega-3 fatty acids were assessed by gas chromatography.
Results
In fully adjusted multivariate analyses, alcohol intake In fully adjusted multivariate analyses, alcohol intake was positively associated with plasma EPA, DHA and EPA + DHA concentrations (p < 0.0001, p < 0.036 and p < 0.002 respectively) in women. EPA and EPA + DHA index in red blood cells were also positively associated with alcohol intake in females (p < 0.0001 and p < 0.037 respectively). In men, only plasma and red blood cell EPA concentrations were linked with intake of alcohol (p < 0.003 and p < 0.004 respectively).
In wine drinkers, stratified analyses revealed a statistically significant positive association between alcohol intake and both plasma and red cell EPA, DHA and the EPA + DHA index. In contrast, no association was found in those who drink beer and spirits.
Comments
This study examined three different populations with different dietary habits who consumed different types of alcoholic beverages. Analyses carried out on different beverages showed that the link between alcohol and omega-3 fatty acids was present in both wine drinkers and beer or spirits drinkers. However, adjusting for alcohol content of alcoholic beverages abolished the association with omega-3s in beer or spirits drinkers, while the associations with EPA and DHA were maintained or strengthened in wine drinkers.
These findings suggest that components in wine other than alcohol may be responsible for the higher omega-3 concentrations observed. The study authors propose that the polyphenol antioxidant components of wine may stimulate the synthesis of EPA and DHA from the precursor alpha-linolenic acid. Polyphenols may also be involved in that process by preventing alcohol-induced oxidation of long chain fatty acids, thus delaying their breakdown.
Reference de Giuseppe R, et al. Alcohol consumption and n-3 polyunsaturated fatty acids in healthy men and women from 3 European populations. Am J Clin Nutr 89:354-62, 2009.
According to a meta-analysis (1) published in the June issue of Archives of Ophthalmology, a higher intake of the omega-3 fatty acids EPA and DHA reduced the risk of age-related macular degeneration (AMD). In analyzing 9 studies that included roughly 88,900 participants, the Australian authors report that higher intakes of EPA and DHA cut the risk of early AMD substantially and yielded a 38% risk reduction for advanced AMD.
Most recently, a study published in the August issue of the American Journal of Clinical Nutrition is the first in Europeans to show a beneficial association between neovascular AMD and the consumption of oily fish (e.g. mackerel, tuna, salmon, sardines, and herring) (2). The study, funded in part by the European Commission and the Macular Disease Society UK, is consistent with results from studies in the US and Australia.
Study Design and Methods
The EUREYE study is a cross-sectional population-based study in persons aged 65 years or older in 7 centers located from north to south Europe. Participants in the cross-sectional population-based EUREYE study underwent fundus photography and were interviewed by using a food-frequency questionnaire. Fundus images were graded by the International Classification System for Age Related Maculopathy.
Questionnaire data were converted to nutrient intakes with the use of food-composition tables. Survey logistic regression was used to calculate odds ratios (ORs) and 95% CIs of energy-adjusted quartiles of EPA or DHA with neovascular AMD, taking into account potential confounders.
Results
Dietary intake data and fundus images were available for 105 cases with neovascular AMD and for 2170 controls without any features of early or late AMD.
Eating oily fish at least once per week compared with less than once per week was associated with a halving of the odds of neovascular AMD (OR = 0.47; 95% CI: 0.33, 0.68; P = 0.002). Compared with the lowest quartile, there was a significant trend for decreased odds with increasing quartiles of either DHA or EPA. Odds ratios in the highest quartiles were 0.32 (95% CI: 0.12, 0.87; P = 0.03) for DHA and 0.29 (95% CI: 0.11, 0.73; P = 0.02) for EPA.
In short, habitual consumption of oily fish at least once a week was linked to a 50% reduction in the risk of developing wet AMD. Further, people who consumed at least 300 mg per day of DHA and EPA were 69% less likely to have wet AMD then those consuming less.
References
Chong EW-T, et al. Dietary n-3 fatty acids and fish intake in the primary prevention of AMD-A systematic review and meta-analysis. Arch of Ophthalmol 126:826-833, 2008.
Augood C, et al. Oily fish consumption, dietary docosahexaenoic acid and eicosapentaenoic acid intakes, and associations with neovascular age-related macular degeneration. Am J Clin Nutr 88:398-406, 2008.
Dry, atrophic, or non-exudative, age-related macular degeneration (AMD) is the most common form of the disease, and is characterized by progressive devitalization of retinal pigment epithelium (RPE) and the formation of fatty deposits under the RPE known as soft drusen. Patients not receiving treatment have demonstrated a loss of visual acuity at 6 months of at least 0.8 lines and up to 1.5 lines.
Studies have suggested that nutritional factors can play a significant role in slowing the onset or limiting the effects of AMD. In 2004, the Lutein Antioxidant Supplementation Trial (LAST) demonstrated that nutritional supplementation with lutein or lutein together with antioxidants, vitamins and minerals improved visual function and symptoms in male patients with atrophic AMD (1). Currently, the 2nd Age-Related Eye Disease Study (AREDS II) is examining the effects of carotenoids and omega-3 fats on AMD.
The Taurine, Omega-3 Fatty Acids, Zinc, Antioxidant, Lutein (TOZAL) study was conducted to investigate the impact of combined omega-3, antioxidants, and other nutrients on visual function in those with atrophic AMD (2). The results suggest that such a nutritional approach may help maintain visual acuity.
Study Design and Methods
The primary objective of this prospective, open case-controlled study was to measure the change from baseline in visual function - Best-Corrected Visual Acuity (BCVA) via the ETDRS chart, contrast sensitivity, central 10 degree visual fields and retinal imaging (angiograms and photographs) at 6 months in subjects with atrophic (dry) AMD treated with a targeted nutritional supplement.
Thirty seven mixed gender patients with a mean age of 76.3 +/- 7.8 years were enrolled at 5 independent study sites and received standard of care along with a nutritional supplement containing lutein; zeaxanthin; vitamins A,C and E; beta-carotene; taurine; zinc, copper; EPA and DHA. Results were compared to a placebo cohort constructed from the literature that was matched for inclusion and exclusion criteria. A paired t-test was used to test a null hypothesis and a two-sided alpha level of 0.05 was used to determine statistical significance.
Results
Seventy-six percent of subjects receiving the nutritional supplement demonstrated stabilization or improvement of BCVA at 6 months. Subjects gained an average of 0.0541 logMAR or one-half of a line of visual acuity (VA) over the 6-month period. There was a statistically significant improvement in VA from baseline (p = .045).
Comments
"The results provide strong evidence that the treatment being studied produces an improvement in VA" according to the authors. Supplementation increased VA above the expected baseline decrease in the majority of patients in this population. The results of the TOZAL study agree with the LAST and CARMIS studies and are predictive for positive visual acuity outcomes in the AREDS II trial. However, supplementation for longer than 6 months is likely required to effect changes in additional visual parameters.
References
Richer S et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study. Optometry 75:216-230, 2004.
Cangemi FE, et al. TOZAL Study: An open case control study of an oral antioxidant and omega-3 supplement for dry AMD. BMC Ophthalmology 7:3, 2007.
Sartore M et al. CARMIS Research Group: Effects of short-term supplementation with carotenoids and antioxidants on visual acuity and visual function in age related macular degeneration. Presented at: ARVO; April 30-May 4, 2006; Fort Lauderdale, FL.
According to AMD Alliance International, AMD affects approximately 25-30 million people worldwide, and the incidence of this disease is projected to triple by 2025. New treatments for AMD are limited to patients with exudative AMD and are not without risks. Thus, primary prevention of AMD by modifying risk factors remains an important public health strategy.
Insufficient intake of certain dietary components may be one of those risk factors. There is growing interest in the long - chain omega-3 fatty acids EPA and DHA since they play an important role in the layer of nerve cells in the retina and may be involved in the prevention or progression of AMD.
Epidemiological studies have generally shown inverse associations between intake of these fatty acids from fish and AMD. Now, a systematic review and meta-analysis from the University of Melbourne reports that higher intakes of EPA and DHA significantly decrease the risk of both early and late AMD (1).
Study Design and Methods
Seven databases were systematically searched using standardized criteria, with no limits on publication year or language. Randomized controlled trials and prospective cohort, case-control, and cross-sectional studies were included. Of 2,754 abstracts identified, 3 prospective cohort, 3 case-control, and 3 cross-sectional studies met the criteria. Measures of associations were pooled quantitatively using meta-analytic methods.
Results
Nine studies provided data on a total sample of 88,974 people including 3,203 AMD cases.
A high dietary intake of omega-3 fatty acids was associated with a 38% reduction in the risk of late AMD, when the highest intake was compared with the lowest (pooled odds ratio [OR], 0.62; 95% confidence interval [CI], 0.48-0.82).
Fish intake at least twice weekly was associated with a 24% and 33% reduced risk of early and late AMD respectively (pooled OR, 0.76; 95% CI, 0.64-0.90; and pooled OR, 0.67; 95% CI, 0.53-0.85).
Combining the results from all 9 studies also showed that a high dietary intake of EPA was linked to a 23% lower risk of early AMD, while DHA was associated with a 30% reduction.
In contrast, a high intake of the omega-3 alpha linolenic acid was associated with a 49% increase in risk.
Comments
In this study the definition of 'early AMD' included vision loss, and hence might be more indicative of an intermediate stage of AMD. However, the findings suggest that a greater intake of EPA and DHA can slow AMD progression. In addition, results from the current analysis are consistent with another systematic review in which the authors critically reviewed 6 observational studies for evidence that omega-3 fatty acids prevent AMD (2).
While the benefits of EPA and DHA require confirmation in long-term intervention trials such as AREDS-2, the authors underscore the strong underlying biological rationale of these fatty acids.
DHA plays an essential structural role in the membrane of the retina and is found in high concentrations. Further, the outer photoreceptor cell segments of the retina are constantly shed in the normal visual cycle and deficiency of DHA could initiate AMD.
According to the authors: "There is also evidence that such long-chain fatty acids protect against oxygenic, inflammatory, and age-associated pathology of the vascular and neural retina, which are possible pathogenic factors for AMD development."
References
W-T Chong E, et al. Dietary omega-3 fatty acid and fish intake in the primary prevention of age-related macular degeneration. A systematic review and meta-analysis. Arch Ophthalmol 126:826-33, 2008.
Hodge WG, et al. Efficacy of omega-3 fatty acids in preventing age-related macular degeneration: a systematic review. Ophthalmology 113:1165-1172, 2006.
Dietary data was collected from participants when they enrolled in the AREDS trial so that investigators could later examine the relationship of AMD case groups with intake levels of individual nutrients.
To explore these relationships, AREDS subjects were divided into four groups based on increasing severity of drusen or type of AMD. The dietary information from those four groups was then compared with that from AREDS participants categorized as being 'free' of AMD. AMD-free was defined as having no drusen or less than 15 small drusen. Nutrient intake values were adjusted for energy intake then stratified into quintiles.
Results of the analyses were published in the May and September issues of the journal Archives of Ophthalmology. The first of these case-control studies reports on the relationship of dietary lipids and AMD (1), while the second study assessed whether nutrients such as carotenoids, vitamins A, C and E and others, were related to AMD risk (2).
Omega-3 and Fish Intake Lower AMD Risk
The researchers found that only higher intake of total long chain omega-3 and fish (the primary dietary source of EPA and DHA), were linked to a decreased likelihood of having neovascular AMD. Benefit was not seen for the other AMD groups.
Arachidonic acid was the only dietary lipid directly associated with neovascular AMD prevalence. Participants getting the most arachidonic acid in their diets were 54% more likely to have late AMD. Arachidonic acid, an omega-6 fat abundant in meat and dairy, is a precursor for inflammatory eicosinoids.
No statistically significant relationships were seen for other dietary lipids such as the monounsaturates, found in olive oil for example, or saturated fats.
It's interesting to note that the omega-3 fat alpha-linolenic acid, found in flaxseed oil for example, was associated with decreased AMD risk only when it was included along with EPA and DHA as part of the total intake of long chain polyunsaturated fats. Assessed alone, alpha-linolenic was not related to AMD. Alpha-linolenic acid must first be metabolized to EPA to provide anti-inflammatory activity, and this conversion is only 10-20% effective.
Comparing the highest to lowest quintiles, those consuming the most total omega-3 fats were about 39% less likely to have neovascular AMD. Risk reduction for greater fish intake was the same. A 46% lower chance of having late AMD was linked with the highest consumption of DHA.
EPA, DHA and arachidonic acid are major fatty acids in the diet. Both arachidonic acid and DHA (which can be formed from EPA), are key components of retinal photoreceptor outer segments and vascular tissue. While all three of these lipids are essential, a better balance of EPA and DHA to arachidonic acid is recommended for cardiovascular health. This study strongly suggests that improving that balance can favorably influence retinal health as well.
Only Lutein / Zeaxanthin Independently Linked to AMD
Higher dietary intake of lutein and zeaxanthin was independently associated with a reduced likelihood of having neovascular AMD, geographic atrophy, and large or extensive intermediate drusen. No other nutrients were independently related to AMD.
After adjusting for total energy intake and other non-nutritional risk factors, subjects consuming the highest amount of lutein and zeaxanthin were 35% less likely to have neovascular AMD and 55% less likely to have geographic atrophy than those eating the least. Those whose diets provided the most of these two carotenoids also had a 26% reduced likelihood of having large or extensive drusen.
The findings from both of these AREDS case-control studies are, in part, the basis for testing 10 mg of lutein, 2 mg of zeaxanthin, 650 mg EPA and 350 mg of DHA in the AREDS 2 trial currently underway.
References
AREDS Report No. 20: The relationship of dietary lipid intake and age-related macular degeneration in a case-control study. Arch Ophthalmol 125:671-9, 2007.
AREDS Report No. 22: The relationship of dietary carotenoids with age-related macular degeneration in a case-control study. Arch Ophthalmol 125:1225-32, 2007.
Retinopathy affects an estimated 4 million diabetic patients and about 40,000 premature infants in the US. Retinopathy has two critical phases: loss of vessels in the retina which leads to hypoxia, followed by new vessel growth spurred by the lack of oxygen. The new vessels grow abnormally, are malformed, leaky and over-abundant. In the later stages of the disease, the abnormal vessels pull the retina away from its supporting layer, and the detachment ultimately results in blindness.
The role of omega-3 lipids in angiogenesis is beginning to be defined, and it appears that EPA and DHA are involved in regulating vessel loss and neo-vascularization.
In a study published in the July issue of Nature Medicine, omega-3 fatty acids protected against the development and progression of retinopathy in mice. It was found that increasing tissue levels of EPA and DHA decreases the area of vascular loss in the retina by increasing normal vessel regrowth after injury, and by reducing the hypoxic stimulus for growth of abnormal vessels.
The study was a collaborative effort by researchers at Children's Hospital Boston, Brigham and Women's Hospital, Massachusetts General Hospital, the University of Göteborg in Sweden, and the National Eye Institute. The authors concluded that "supplementing omega-3 polyunsaturated fatty acid intake may be of benefit in preventing retinopathy".
Study Summary
Mice subjected to oxygen-induced retinopathy were fed isocaloric diets enriched with 2% fatty acids - either omega-3 (EPA and DHA) or omega-6 (arachidonic acid). Additionally, the researchers also examined retinopathy in the Fat-1 model. Fat-1 mice are genetically altered to convert omega-6 to omega-3 - a conversion that humans and other mammals cannot do.
Mice receiving the omega-3 rich diet were observed to have 40-50% less initial retinal vessel loss compared to omega-6 fed mice. As a result, the omega-3 group had a similar 40-50% reduction in pathological vessel growth. The results were virtually identical in the Fat-1 mice, confirming that increased retinal omega-3 levels inhibited neo-vascularization.
Omega-3 Protective Mechanism
The investigators demonstrated that the omega-3 diet suppressed production of the cytokine called TNF-alpha, reducing the inflammatory response in the retina. In contrast, the arachidonic enriched diet increased TNF-alpha production. The retinas of the omega-3 group also had higher levels of neuroprotectin D1 and resolvin D1 (both derived from DHA), and resolvin E1, which is derived from EPA. These compounds also potently protected against pathological vessel growth, and were not detected in retinas of the omega-6 fed mice.
Commentary
"It is remarkable that with only a 2% change in dietary omega-3 intake, we observed an approximate 40-50% decrease in retinopathy severity", commented one of the study's lead authors Dr. Kim Connor. "Our studies suggest that after initial loss, vessels re-grew more quickly and efficiently in the omega-3 fed mice", said Connor. "This increased the oxygen supply to retinal tissue, resulting in a dampening of the inflammatory alarm signals that lead to pathological vessel growth".
According to the other lead author, Dr. John Paul SanGiovanni, "this is a major conceptual advance in the effort to identify modifiable factors that may influence inflammatory processes implicated in the development of common sight-threatening retinal disease".
The American Diabetic Association currently advises people with diabetes to consume more omega-3 to lower their risk of heart disease. If the findings of this study are confirmed in humans, fish oil may also lessen the risk for one of the long-term complications of diabetes, retinopathy. A clinical trial at Children's Hospital Boston is set to test the effects of omega-3 supplementation in premature infants at risk of retinopathy.
Reference
Connor KM et al. Increased dietary intake of 3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nature Medicine 13:868-874, 2007.
Retinitis pigmentosa (RP) refers to a group of inherited progressive retinal dystrophies characterized by photoreceptor degeneration. The rods are affected initially, followed by gradual death of the cones. It's estimated that 1 in 4,000-5,000 people have RP worldwide. Since no generally accepted medical or surgical treatment can stop the course of the disease, researchers have undertaken studies with various nutritional supplements in hopes of improving visual function or slowing disease progression. Along with vitamin A , DHA and an omega-3 rich diet, lutein has recently been reported to be of potential benefit in RP.
Lutein May Benefit Visual Field and Acuity
Spurred by previous studies suggesting lutein as a potential treatment with positive effects on macular pigment density, researchers from the Wilmer Eye Institute conducted a double-blind, randomized placebo-controlled trial with a cross-over design (1). Thirty-four adult RP patients were randomized to 2 groups and followed for 48 weeks. One group received lutein supplements (10 mg/day for 12 weeks followed by 30 mg/day) for the first 24 weeks, then placebo for the following 24 weeks. The second group received placebo prior to lutein. Both groups were given a multi-vitamin and mineral supplement.
Lutein supplementation had a significant effect on central visual field. Visual acuity also improved slightly, though no effect on contrast sensitivity was observed. Comparing the development of vision measures against the natural loss expected to occur over 48 weeks, most measures showed reduced decline. These reductions were significant for normal illumination visual acuity and contrast sensitivity. The results, according to the authors, suggest that lutein supplementation improves visual field and may also modestly improve visual acuity.
Vitamin A Helps Preserve Visual Function
In 1993, Harvard investigators reported that 15,000 IU of vitamin A palmitate slowed the rate of decline of retinal function over 5 years as measured by ERG (2). In this study of 600 RP patients, high dose vitamin A helped preserve retinal function, while those getting high dose vitamin E (400 IU) were more likely to show a functional decline. A later study following adult RP patients taking high dose vitamin A for about 12 years concluded that prolonged intake is considered safe in this age group (3), although routine monitoring of liver function and fasting serum vitamin A levels are advised. Women of childbearing age should not take high dose vitamin A, which may raise the risk of birth defects.
Antioxidants Protect Cones in Animal Model
Why the negative affect of high dose vitamin E on RP function? It is possible that high dose vitamin E might have inhibited the absorption or transport of vitamin A, since patients receiving high doses had slight but significant decreases in serum A levels compared with those receiving lower doses in the 1993 Harvard study.
However, further exploratory studies of combined antioxidants in RP patients may be warranted. A recent study in an animal model of RP found that high dose antioxidants (vitamins E, C, alpha lipoic acid others) significantly reduced oxidative damage in cones, increased cone cell density and preserved cone function. These results, according to the Johns Hopkins authors, suggest that the gradual cone death that occurs after rod cells die is due to oxidative damage, and that antioxidants could provide benefit (4).
Omega-3 Fatty Acids Support Visual Field
While a 4 year long study published in 2004 reported that 1,200 mg of supplemental DHA along with high dose vitamin A did not slow the course of RP overall, further subgroup analysis showed benefit for those starting vitamin A supplementation for the first time (5,6). In addition, those study participants taking vitamin A (but not DHA) who also had a higher dietary omega-3 intake experienced substantial benefit. The rate of visual field decline was retarded by 40-50% yearly in those whose omega-3 intakes were equivalent to 1-2 servings of fatty fish weekly.
References
Bahrami H, et al. Lutein supplementation in retinitis pigmentosa: PC-based vision assessment in a randomized double-masked placebo-controlled clinical trial. BMC Ophthalmology 6:23, 2006.
Berson EL, et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol 111:761-72, 1993.
Sibulesky L, et al. Safety of <7500 RE (<25,000 IU) vitamin A daily in adults with retinitis pigmentosa. Am J Clin Nutr 69:656-63, 1999.
Komeima K, et al. Antioxidants reduce cone cell death in a model of retinitis pigmentosa. PNAS 103:1130-35, 2006.
Berson EL, et al. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch Ophthalmol 122:1297-305, 2004.
Berson EL, et al. Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa. 12:1306-14, 2004.
While the relationship between the omega-3 fatty acids and age related cognition and retinal function have only recently begun to emerge, the cardio-vascular effects of EPA and DHA have been studied for nearly three decades. Interest in these fatty acids from cold water fish began in the late 1970's when studies revealed that Greenland's indigenous Inuits had a significantly lower rate of heart attack compared with Western control subjects. These observations generated an estimated 5000 studies to explore this and other effects of omega-3 fats, and ultimately led to the American Heart Association's recommendations for regular omega-3 consumption in 2002. Research continues to support the cardio-protective role of these fatty acids as evidenced by the findings of several newly published studies.
Fish Fatty Acids More Effective Than Defibrillators
Omega-3 fatty acids may prevent more sudden deaths than automated external defibrillators (AED) in homes and public places or implanted defibrillators according to results of a study supported by the Centers for Disease Control (1). Researchers compared these preventive strategies in a computer-simulated community of 100,000 people that resembled the population of Olmsted County, Minnesota.
Raising the omega-3 fatty acid levels among the cyber-Olmsted citizens resulted in lowering overall mortality rates by 6.4%. In contrast, AEDs reduced death rates by 0.8% and implanted defibrillators (ICDs) lowered the rates by 3.3%. Three-quarters of the reduction in deaths from increased omega-3 levels would come from raising them among the healthy portion of the population.
Raising blood levels of the omega-3 in people after a heart attack could save 58 lives yearly according to the simulation's predictions, while only 7 lives were saved by AEDs and implanted defibrillators prevented 30 deaths yearly. While heart attack survivors are routinely given omega-3 supplements in some European countries, this is generally not the case in the U.S., though the evidence supports it. According to a study published in the September issue of the Journal of the American Board of Family Medicine, only 17% of family doctors were likely to advise patients - including those who had suffered a heart attack - to take omega-3 supplements (2). There is a great need, the authors concluded, to "improve awareness of this important advice."
Heart Benefits Confirmed In Systematic Review
A recently published systematic review of randomized controlled trials, prospective cohort and case-control studies, concludes that the evidence suggests that fish or fish oil supplements reduces the rates of all cause mortality, cardiac and sudden death, and possibly stroke(3). The evidence was stronger for secondary than primary prevention.
Commissioned by the NIH, the review found that increased consumption of EPA and DHA - but not the omega-3 fatty acid alpha linolenic (ALA) - reduces the rates of these CVD outcomes. Data on the effects of ALA, found in flaxseed and other vegetable oils, were reportedly limited and typically of poor quality.
Future Directions: An Omega-3 Index
A second review published online in August ahead of print in the journal Cardiovascular Research, also concludes that the majority of the evidence supports the benefits of omega-3 intake for heart health. The authors, from Saint Luke's Hospital, University of Missouri-Kansas City School of Medicine, have proposed an omega-3 index as a modifiable risk factor for CVD. The Index measures the sum of EPA+DHA in the membrane of erythrocytes as the percent of all fatty acids in the red blood cell membrane. The authors also determined that membrane EPA+DHA index equal to or exceeding 8% is associated with the greatest cardio-protection. In the future, this measure of EPA/DHA status could help physicians tailor advice to their patients to help them achieve levels of omega-3 scientifically reported to provide CVD benefits.
References
Kottke TE, et al. Preventing sudden death with n-3 (omega-3) fatty acids and defibrillators. Am J Prev Med 31:316-23, 2006.
Oh RC, et al. The fish in secondary prevention of heart disease (FISH) survey-primary care physicians and omega-3 fatty acid prescribing behaviors. J Am Board Fam Med 19:459-67, 2006.
Wang C, et al. n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am J Clin Nutr 84:5-17, 2006.
Reviewers from the National Eye Institute recently summarized the functions of the omega-3 fatty acids eicosapentenoic acid (EPA) and docosapentaenoic acids (DHA) in retinal tissues. [See EduFacts, Vol. 5 No 7]. According to the reviewers, studies looking at the relationship of the omega-3 fats to the prevalence of advanced AMD have generally observed a protective effect. A new study by Australian researchers adds to this growing body of evidence, and suggests that regularly consuming omega-3 fat, especially from fish, protects against early and late AMD in older individuals (1).
Design and Methods
To assess longitudinal associations between dietary fat and incident AMD, dietary intakes were measured by food frequency questionnaires at baseline in 2895 participants of the Blue Mountains Eye Study (BMES). Since the questionnaires can under- or over-report food consumption, dietary data were verified in a sub- group of participants who completed 4-day weighed food records 3 times over the course of a year. The results were generally in good agreement with the questionnaire data. Seventy five percent of the BMSE cohort (2335 persons) was re-examined after 5 years. Presence of AMD was graded from retinal photographs (Wisconsin ARM Grading System). Logistic regression adjusted for age, sex, vitamin C intake and smoking.
Results
The researchers examined the risk of incident AMD participants in the lowest and highest quintiles of dietary fat intakes with respect to the 60% of the population who represent a moderate, normal intake, or those in the middle 3 quintiles. Participants in the highest vs. the lowest quintiles of omega-3 fat intake had a lower risk of incident early AMD (odds ratio 0.41 [0.22-0.75])
A 40% reduction of incident early ARM was associated with fish consumption at least once a week (odds ratio 0.58 [0.37-0.90]). Consuming fish at least 3 times weekly resulted in about a 70% reduction in the incidence of late AMD (odds ratio 0.25 [0.06-1.00]). (See Table)
When the intake of specific types of fats was calculated, a trend toward increased risk of developing early AMD was noted for people with the lowest intake of monounsaturated fats and omega-3 including alpha-linolenic acid.
Comments
Though several population health studies have linked high dietary fat intake from any source to increased AMD risk, this study found no evidence that dietary fat of any kind raised that risk. The findings are largely in agreement with other studies showing that diets high in omega-3 fatty acids, particularly DHA derived largely from fish, may protect against retinal oxidation and degeneration, according to the authors. They propose that insufficient omega-3 intake could cause abnormal metabolism in the retina and affect cell renewal.
ORs and CIs of Early and Late ARM with Increasing Frequency of Certain Food Types in BMES Participants*
5-y Incidence, OR (95% CI)
Early ARM (n = 130)
Late ARM (n = 22)
Margarine
<1/wk
1.00 (Reference)
1.00 (Reference)
1-6/wk
.89 (0.57-1.38)
1.55 (0.44-5.40)
Daily
0.87 (0.58-1.29
0.85 (0.33-2.22)
Butter
<1/wk
1.00 (Reference)
1.00 (Reference)
1-6/wk
0.48 (0.22-1.02)
0.82 (0.18-3.76)
Daily
0.77 (0.48-1.24)
0.85 (0.27-2.66)
Total Fish †
< 1/mo
1.00 (Reference)
1.00 (Reference)
≥1/wk
0.48 (0.37-0.90)
0.44 (0.16-1.21)
≥3/wk
0.62 (0.38-1.03)
0.25 (0.06-1.00)
Nuts
Never
1.00 (Reference)
1.00 (Reference)
≥ 1/wk
0.80 (0.52-1.25)
0.82 (0.29-2.34)
≥ 1/wk
0.79 (0.46-1.34)
0.55 (0.14-2.16)
Abbreviations: ARM, age-related maculopathy; BMES, Blue Mountains Eye Study; CI, confidence interval; OR, odds ratio. *Food types are categorized by frequency of servings. † Includes sardines, tuna, and other fish.
References
Chua B, et al. Dietary fatty acids and the 5-year incidence of age-related maculopathy. Archives Ophthalmol 124:981-6, 2006.
A paper E-published in March, 2006 reports on the role that the omega-3 fatty acid docosahexaenoic acid (DHA) in fish oil plays in protecting cells in the retina from degenerative diseases like age-related macular degeneration and retinitis pigmentosa (1).
In both of these blinding eye diseases, photoreceptors (rods and cones) degenerate and die. Although this process can be triggered by many different things, one of the most significant protective factors may be the close association of retinal pigment epithelial cells (RPE) and the amount of DHA they contain.
The main role of RPE cells is photoreceptor maintenance. RPE cells conduct the daily shedding, internalization and degradation of the tips of photo-receptor outer segments. Now it appears that RPE cells are also crucial to the survival of photoreceptor cells.
Closer to Solving a Complex Riddle
Both RPE and photoreceptor cells are exposed to potentially damaging factors such as sunlight and high oxygen tension on a daily basis. It's known that antioxidants such as lutein afford some protection, but exactly how these cells avoid harm from these and other factors, has been somewhat of a mystery up to now. However, Nicolas Bazan, MD, PhD, Director of the Neuroscience Center of Excellence at LSU Health Sciences Center in New Orleans, working in col- laboration with Harvard researchers, has made several important discoveries that are beginning to provide answers to this complex question.
One of the answers is the importance of DHA. RPE cells cope with UV and oxidative stress, as well as trauma, by using antioxidants like vitamin E present in cellular membranes. Part of the RPE cells' response to these insults is to activate the synthesis of a major neuroprotective compound called neuroprotectin D1 or NPD1. Oxidative stress and other triggers turn on genes that lead to inflammation and cell death. NPD1 inhibits these genes. RPE cells contain DHA, which has been found to be the precursor to NPD1.
RPE cells regulate the uptake, conservation and delivery of DHA to photoreceptor cells. In addition to stimulating the production of NDP1, DHA promotes protective cell signaling by facilitating the expression of helpful rather than destructive proteins. DHA and NPD1 also decrease the production of damaging free radicals.
DHA is known to be in short supply in patients with retinitis pigmentosa and Usher's syndromes, and an oral supply of DHA has been shown to improve the condition of retinitis pigmentosa patients with chronic progressive neurodegeneration (2). Additionally, studies have found that higher dietary intake of DHA is associated with AMD risk reduction. DHA has been shown to promote the survival and inhibit cell death not only of photoreceptor cells, but also of neurons in an experimental model of Alzheimer's disease.
Other important questions remain, including the identification of another receptor believed to be an important pathway for NPD1, and more information is needed about the signals that control NPD1 formation. It's important to define these initial events, notes Dr. Bazan, since early clinical manifestations of retinal degeneration precedes massive photoreceptor cell death.
Physiological and pathological features of DHA in photoreceptors
Photoreceptor outer segments have the highest DHA content of any cell and have unusual DHA-retention ability.
Prolonged dietary deprivation of omega-3 fatty acids is required to reduce DHA content. Only then do function impairments occur.
During outer-segment renewal, the retinal pigment epithelium (RPE) recycles DHA back to the inner segments.
DHA-supplemented infant formulas enhance:
Maturation of retinal function
Visual acuity
Overall neurological performance in pre-term and term infants
Blood DHA levels are decreased in various forms of retinitis pigmentosa, in Usher's syndrome, and in animal models of inherited retinal degeneration.
Rodents with rhodopsin mutations that are homologous to mutations in human retinitis pigmentosa display decreased levels of DHA in photoreceptors.
In age-related macular degeneration, there is an inverse relationship between diets high in DHA and risk for the disease
References
Bazan NG. Review. Cell survival matters: docosahexaenoic acid signaling neuroprotection and photoreceptors. Trends in Nueroscience. [Epub ahead of print], March 30, 2006.
Berson EI, et al. Further evaluation of DHA in patients with retinitis pigmentosa receiving vitamin A treatment subgroup analyses. Arch Ophthalmol 122:457-64, 2004.
A Harvard research team led by Dr. Johanna Seddon notes that age-related macular degeneration (AMD) and cardiovascular disease (CVD) share common risk factors, such as smoking and higher body mass index (BMI). They propose that mechanisms involved in developing AMD could be better understood by evaluating biomarkers of CVD. A number of analyses, in fact, have shown that systemic biomarkers for inflammation and artery damage, including C-reactive protein (CRP) and homocysteine (HCY), are related to AMD. Basic research also demonstrates that inflammatory, immune and atherosclerotic processes are related to AMD development.
To further explore mechanisms related to AMD pathogenesis, these researchers evaluated the relationships between CRP, HCY and other known risk or protective factors for AMD in subjects from the original AREDS trial (1). According to Dr. Seddon, the findings indicate that "sick eyes may occur in sick bodies related to smoking, overweight, inadequate nutrient intake, and other unhealthy behaviors".
Study Design
After randomization for AREDS, 934 subjects from two clinical sites underwent blood draws, measurements, photographs of the macula and answered questionnaires. Dietary, behavioral and medical risk, and protective factors for AMD were evaluated for their associations with blood values of CRP and HCY. This original data provided information on intake of fish as well as antioxidants such as vitamins C and E, alpha- and beta-carotene and lutein/zeaxanthin. In addition, serum nutrient values obtained from participants at one of the sites were also evaluated for their association with CRP and HCY. Multivariable regression analyses were performed after adjusting for age, gender and AREDS treatment.
Results
Higher levels of serum antioxidants vitamin C and lutein/zeaxanthin and higher fish intake (a source of omega-3 fats) were associated with lower serum CRP levels. CRP levels decreased 2 milligrams per litre for every 1000 microgram per decilitre increase in blood levels of lutein/zeaxanthin. A 0.2 milligram per litre decrease in CRP was also associated with more than 2 servings of fish weekly.
Increased BMI and smoking were associated with increased CRP, while serum alpha-carotene, dietary intake of antioxidants and vitamin B6 were associated with lower levels of plasma HCY. Levels of HCY were observed to be higher in those with hypertension. While serum vitamin E was linked to lower concentrations of HCY, it was unexpectedly linked to higher levels of CRP.
Comments
Factors reported to be related to AMD, namely antioxidants, smoking, BMI, HCY (2) and fish intake, are also associated with inflammatory, immune, or other CVD mechanisms. These results are consistent with previous findings associating smoking, BMI, and the biomarkers CRP and interleukin-6 with AMD in a different study cohort of AMD patients (3).
The relationship between fish intake, BMI, and levels of inflammatory markers have been previously reported in other "non-ocular" study populations. These data support and expand on these associations. The positive link between higher vitamin E and CRP deserves further study, according to the authors. This finding disagrees with the recent Rotterdam study, which found that vitamin E significantly lowered AMD risk [EduFacts Vol.6 No.1].
Overall, the Harvard study adds to a growing body of data showing a protective effect of antioxidants such as lutein/zeaxanthin, and omega-3 fats against AMD.
References
Seddon JM et al. C-reactive protein and homocysteine are associated with dietary and behavioral risk factors for age-related macular degeneration. Nutrition 22:441-43, 2006.
Seddon JM et al. Evaluation of homocysteine and risk of age-related macular degeneration. Am J Ophthalmol 141:201-3, 2006.
Seddon JM et al. Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin-6, and other cardiovascular biomarkers. Arch Ophthalmol 123:774-82, 2005.
The omega-3 fats EPA and DHA are mainly obtained from coldwater fish, while the more commonly consumed omega-6 fats primarily come from vegetable oils, meats and dairy products. Evidence suggests that the high ratio of omega-6 fats to low levels of omega-3 fats currently consumed in the U.S. promotes a number of chronic diseases (1). For example, the cardio-protective benefits of consuming more omega-3 are well established. Studies looking at the relationship of omega-3 to the prevalence of advanced AMD have also observed a protective effect [see table below].
Omega-3 & Major Retinal Diseases
A newly published review of omega-3 functions in the retina from the NEI Division of Epidemiology and Clinical Research supports those observations. According to the reviewers, consistent evidence suggests that the omega-3 play a pivotal role in protecting the vascular and neural retina (2).
The authors discuss omega-3 related bioactive compounds in relation to three retinal diseases of major public health significance: ARMD, diabetic retinopathy and retinopathy of prematurity EPA and DHA may protect against factors and processes involved in the pathology of the retina's vasculature and nerve cells such as ischemia, damage from light exposure, reactive oxygen species and free radicals, inflammation and age-related retinal changes.
General Function of the Omega-3
Lipids found in cellular membranes reflect the type of dietary fats we consume. Tissue status of long-chain omega-3 can be modified by - and is dependent on - our dietary intake of these fatty acids. In nerve cell membranes omega-3 serve structural and function roles. They maintain membrane fluidity and flexibility, and modulate ion channels, receptors and ATPases. They also serve as precursors for the formation of eicosanoids, a family of hormone-like agents that act locally in the cells that make them or in adjacent cells. Eicosanoids influence processes such as inflammation, vessel dilation and constriction, clotting, the movement of calcium in and out of cells, and cell division and growth (1).
Omega-3 Role in the Retina
DHA is a major structural component of retinal photoreceptor outer segment membranes, and it affects the permeability, fluidity and thickness of these membranes. The omega-3 can influence such key processes as retinal cell signaling, gene expression, differentiation and retinal cell survival.
Omega-3 also affect the production and activation of angiogenic growth factors, vasoregulatory eicosinoids, and other factors implicated in abnormal retinal neovascularization, vascular permeability and inflammation. The formation of new and abnormal blood vessels, or angiogenesis, is common to 'wet' AMD, proliferative diabetic retinopathy and retinopathy of prematurity. Clarifying the role of omega-3 in retinal health and disease is important since tissue stores can be increased by consuming a better balance of omega-3 to omega-6.
References
Rand Evidence Report 114, commissioned by US Health Department. Effects of omega-3 fatty acids on cognitive function with aging, dementia and neurological diseases. AHRQ No. 05- E011-2, 2005
SanGiovanni JP and Chew EY. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog in Retinal Eye Res 24:87-138, 2005
A unique omega-3 fish oil supplement with lutein
& olive leaf extract
OmegaAdvance provides 500
mg of highly concentrated fish oil that yields 300 mg of EPA
and 200 mg of DHA.
Some products utilize a less concentrated form of fish oil, which
means you need much more of it to obtain the same amount of EPA
and DHA
found in OmegaAdvance. For example, some products providing as much
as 2,000 mg of fish oil yield the same amount of EPA
and DHA
contained in OmegaAdvance.
The scientific support is strong that regular omega-3
intake lowers risk of heart disease; support for visual health is growing
Studies link greater intake or higher blood levels
of EPA
/DHA
with lower risk of AMD
Most people do not obtain enough omega-3 from
their diet and/or are concerned about contaminants in fatty fish:
typical intake is 100 mg EPA
/DHA
daily, while 400-600 mg is advised
Whats the difference between the
EE and TG forms of omega-3s?
Research suggests that the EE (Ethyl Ester)
and TG (triglyceride) forms of omega fatty acids from fish oil are
absorbed about the same when taken over several weeks or more. While
some research measuring absorption over just a single day or less
found the TG form to be better absorbed, differences disappear in
studies that compared these forms over two weeks or more. SBH products
contain the EE form, as the EE form has been used in nearly every
clinical trial showing benefit for omega-3s from fish oil and is the
choice for the National Eye Institutes AREDS 2 trial now in
progress. Learn
more
Whos OmegaAdvance for?
Target audience is wide, and encompasses those:
Concerned about their macular health
Wanting to support heart health
Wanting to help support normal blood sugar metabolism
Possibly those wanting to maintain cognitive
health with age
What are EPA and DHA ?
EPA
and DHA
are long-chain fatty acids found in fatty fish that play important roles
in health
EPA
helps maintain balance of pro- & anti-inflammatory compounds
DHA
is the major structural fatty acid in retinal & brain cell membranes
EPA
& DHA
help keep cell membranes flexible for healthy function
How do omega-3s work?
Research has shown that they:
Promote regular heart beat rhythm
Help maintain healthy triglyceride levels
May slow the growth rate of plaque in blood vessels
Promote a less inflammatory environment
(inflammation is a factor in CVD & likely AMD as well)
Help protect photoreceptor cells (rods &
cones)
What distinguishes OmegaAdvance from other omega-3
products?
OmegaAdvance provides 500 mg of highly concentrated
fish oil that yields 300 mg of EPA
and 200 mg of DHA
. Some products utilize a less concentrated form of fish oil, which
means you need much more of it to obtain the same amount of EPA
and DHA
found in OmegaAdvance. For example, some products providing as much
as 2,000 mg of fish oil yield the same amount of EPA
and DHA
contained in OmegaAdvance.
Extremely Pure
Uses FIRST AND ONLY “pharmaceutical grade” fish oil ingredient to achieve US Pharmacopoeia (USP®) verification – one of the most rigorous quality assurance verifications in the world
Rigorously tested for heavy metals (including
mercury and arsenic) and marine contaminants
Sourced from cold, pristine, deep waters off
South America where there are significantly less environmental impurities
Undergoes multiple tests to ensure stability
and molecular distillation, a purification process that concentrates
omega-3s and helps eliminate contaminants
Very concentrated
Most fish oil contains about 50% or less of omega-3;
OmegaAdvance contains a minimum of 60% (35% EPA
and 25% DHA
)
6 times the amount found in multivitamins such
as Centrum Silver® and One-A-Day®
Reflects pairing of lutein
and omega-3 in the AREDS-2 trial (now in progress)
Contributes the unique polyphenols found in olive
leaf extract
Polyphenols are one of the key components of
olive oil that research suggests may confer heart & blood vessel
benefits
Unique polyphenols found in olive leaf extract
act as potent antioxidants
Contains antioxidants for fish oil stability
Meets omega-3 recommendations by AHA (American Heart
Association)
Natural lemon scent no fishy odor
Reasonably sized softgels
Flexible daily dose to accommodate differences in
fish intake
2 softgels offer flexibility to consumers with
different fish-consumption habits; those who eat cold water fish
1-2 times weekly can take 1 softgel daily
How much omega-3 is recommended by health authorities?
Agency or
Group
ISSFAL
(International Society for Study of Fatty Acids and Lipids)
ADA
(American Diabetes Association)
AHA
(American Heart Association)
OmegaAdvance
Daily Dose
Daily intake
of omega-3 advised (mg)
500-650 mg
400-600 mg
At least 2-3 fish servings weekly (equivalent to about 400-600 mg)
Minimum 400 mg
Everyone: at least 2 servings/week (about 400 mg)
500 mg
Are there any contraindications for OmegaAdvance?
Taking OmegaAdvance with anticoagulants (such as
Coumadin): While the level of EPA
/DHA
in OmegaAdvance is unlikely to cause any increased bleeding problems
in people taking those medication, it is best for those taking anticoagulants
to check with their physician
Utilizes pharmaceutical grade, USP®-Verified Fish oil
500 mg omega-3 level matches current recommendations
Vision-specific formula
Reasonably-sized softgels are easy to swallow
Includes 1.5 mg FloraGLO® lutein for macular health protection
Provides Olive Leaf Extract with antioxidant oleuropein
OmegaAdvance®
Most other fish oils
-
-
-
-
-
-
"We use OmegaAdvance on the advice of our Ophthalmologist and with concurrence of our family physician. Both of them were highly in favor of the lutein and the omega to promote both eye health and circulation."
OmegaAdvance is a highly concentrated, ultra pure fish oil supplement, rich in omega-3 DHA and EPA, that helps to protect macular health and promote a healthy cardiovascular system. It also includes the important eye-specific antioxidants lutein and zeaxanthin as well as olive leaf extract to support vessel health.